SpringWorks Therapeutics Inc (SWTX)
38.19
+2.11
(+5.85%)
USD |
NASDAQ |
Jan 03, 16:00
38.20
+0.01
(+0.03%)
After-Hours: 20:00
SpringWorks Therapeutics SG&A Expense (Quarterly): 61.60M for Sept. 30, 2024
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| Vertex Pharmaceuticals Inc | 371.80M |
| PTC Therapeutics Inc | 73.46M |
| Atara Biotherapeutics Inc | 10.42M |
| Blueprint Medicines Corp | 89.93M |
| Edgewise Therapeutics Inc | 8.21M |